Global Hereditary Angioedema (HAE) Therapeutics Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	161 Pages	TechNavio	July, 2024	INF19384894

Best Price Guarantee
Price	from $2,500
Length	161 Pages
Publisher	TechNavio
Published Date	July, 2024
SKU	INF19384894

Global Hereditary Angioedema (HAE) Therapeutics Market 2024-2028

Global Hereditary Angioedema (HAE) Therapeutics Market 2024-2028

The hereditary angioedema (HAE) therapeutics market is forecasted to grow by USD 2192.1 mn during 2023-2028, accelerating at a CAGR of 10.59% during the forecast period. The report on the hereditary angioedema (HAE) therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of hereditary angioedema, advancements in diagnostic techniques, and growing healthcare infrastructure.

Technavio's hereditary angioedema (HAE) therapeutics market is segmented as below:

By End-user
Hospital pharmacies
Retail pharmacies
E-commerce
By Product
C1-esterase inhibitor
Bradykinin B2 receptor antagonist
Kallikrein inhibitor
Others
By Geographical Landscape
North America
Europe
Asia
Rest of World (ROW)

This study identifies the growing demand for personalized medicine as one of the prime reasons driving the hereditary angioedema (HAE) therapeutics market growth during the next few years. Also, development of innovative and effective therapeutics, such as monoclonal antibodies and gene therapy and increasing r and d and funding for orphan drug development will lead to sizable demand in the market.

The report on the hereditary angioedema (HAE) therapeutics market covers the following areas:

Hereditary angioedema (HAE) therapeutics market sizing
Hereditary angioedema (HAE) therapeutics market forecast
Hereditary angioedema (HAE) therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hereditary angioedema (HAE) therapeutics market vendors that include Adverum Biotechnologies Inc, Arrowhead Pharmaceuticals Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., CENTOGENE NV, Cipla Inc., CSL Ltd., Diapharma Group Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., Pharming Group NV, Sanofi SA, and Takeda Pharmaceutical Co. Ltd.. Also, the hereditary angioedema (HAE) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Executive Summary - Chart on Market Overview; Executive Summary - Data Table on Market Overview; Executive Summary - Chart on Global Market Characteristics; Executive Summary - Chart on Market By Geographical Landscape; Executive Summary - Chart on Market Segmentation by End-user; Executive Summary - Chart on Market Segmentation by Product; Executive Summary - Chart on Incremental Growth; Executive Summary - Data Table on Incremental Growth; Executive Summary - Chart on Company Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Parent Market; Data Table on - Parent Market; 2.2 Market characteristics; Market characteristics analysis; 2.3 Value chain analysis; Value Chain Analysis
3 Market Sizing: 3.1 Market definition; Offerings of companies included in the market definition; 3.2 Market segment analysis; Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Chart on Global - Market size and forecast 2023-2028 ($ million); Data Table on Global - Market size and forecast 2023-2028 ($ million); Chart on Global Market: Year-over-year growth 2023-2028 (%); Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global Hereditary Angioedema (HAE) Therapeutics Market 2018 - 2022; Historic Market Size - Data Table on Global Hereditary Angioedema (HAE) Therapeutics Market 2018 - 2022 ($ million); 4.2 End-user segment analysis 2018 - 2022; Historic Market Size - End-user Segment 2018 - 2022 ($ million); 4.3 Product segment analysis 2018 - 2022; Historic Market Size - Product Segment 2018 - 2022 ($ million); 4.4 Geography segment analysis 2018 - 2022; Historic Market Size - Geography Segment 2018 - 2022 ($ million); 4.5 Country segment analysis 2018 - 2022; Historic Market Size - Country Segment 2018 - 2022 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by End-user: 6.1 Market segments; Chart on End-user - Market share 2023-2028 (%); Data Table on End-user - Market share 2023-2028 (%); 6.2 Comparison by End-user; Chart on Comparison by End-user; Data Table on Comparison by End-user; 6.3 Hospital pharmacies - Market size and forecast 2023-2028; Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%); 6.4 Retail pharmacies - Market size and forecast 2023-2028; Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%); Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%); 6.5 E-commerce - Market size and forecast 2023-2028; Chart on E-commerce - Market size and forecast 2023-2028 ($ million); Data Table on E-commerce - Market size and forecast 2023-2028 ($ million); Chart on E-commerce - Year-over-year growth 2023-2028 (%); Data Table on E-commerce - Year-over-year growth 2023-2028 (%); 6.6 Market opportunity by End-user; Market opportunity by End-user ($ million); Data Table on Market opportunity by End-user ($ million)
7 Market Segmentation by Product: 7.1 Market segments; Chart on Product - Market share 2023-2028 (%); Data Table on Product - Market share 2023-2028 (%); 7.2 Comparison by Product; Chart on Comparison by Product; Data Table on Comparison by Product; 7.3 C1-esterase inhibitor - Market size and forecast 2023-2028; Chart on C1-esterase inhibitor - Market size and forecast 2023-2028 ($ million); Data Table on C1-esterase inhibitor - Market size and forecast 2023-2028 ($ million); Chart on C1-esterase inhibitor - Year-over-year growth 2023-2028 (%); Data Table on C1-esterase inhibitor - Year-over-year growth 2023-2028 (%); 7.4 Bradykinin B2 receptor antagonist - Market size and forecast 2023-2028; Chart on Bradykinin B2 receptor antagonist - Market size and forecast 2023-2028 ($ million); Data Table on Bradykinin B2 receptor antagonist - Market size and forecast 2023-2028 ($ million); Chart on Bradykinin B2 receptor antagonist - Year-over-year growth 2023-2028 (%); Data Table on Bradykinin B2 receptor antagonist - Year-over-year growth 2023-2028 (%); 7.5 Kallikrein inhibitor - Market size and forecast 2023-2028; Chart on Kallikrein inhibitor - Market size and forecast 2023-2028 ($ million); Data Table on Kallikrein inhibitor - Market size and forecast 2023-2028 ($ million); Chart on Kallikrein inhibitor - Year-over-year growth 2023-2028 (%); Data Table on Kallikrein inhibitor - Year-over-year growth 2023-2028 (%); 7.6 Others - Market size and forecast 2023-2028; Chart on Others - Market size and forecast 2023-2028 ($ million); Data Table on Others - Market size and forecast 2023-2028 ($ million); Chart on Others - Year-over-year growth 2023-2028 (%); Data Table on Others - Year-over-year growth 2023-2028 (%); 7.7 Market opportunity by Product; Market opportunity by Product ($ million); Data Table on Market opportunity by Product ($ million)
8 Customer Landscape: 8.1 Customer landscape overview; Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Chart on Market share By Geographical Landscape 2023-2028 (%); Data Table on Market share By Geographical Landscape 2023-2028 (%); 9.2 Geographic comparison; Chart on Geographic comparison; Data Table on Geographic comparison; 9.3 North America - Market size and forecast 2023-2028; Chart on North America - Market size and forecast 2023-2028 ($ million); Data Table on North America - Market size and forecast 2023-2028 ($ million); Chart on North America - Year-over-year growth 2023-2028 (%); Data Table on North America - Year-over-year growth 2023-2028 (%); 9.4 Europe - Market size and forecast 2023-2028; Chart on Europe - Market size and forecast 2023-2028 ($ million); Data Table on Europe - Market size and forecast 2023-2028 ($ million); Chart on Europe - Year-over-year growth 2023-2028 (%); Data Table on Europe - Year-over-year growth 2023-2028 (%); 9.5 Asia - Market size and forecast 2023-2028; Chart on Asia - Market size and forecast 2023-2028 ($ million); Data Table on Asia - Market size and forecast 2023-2028 ($ million); Chart on Asia - Year-over-year growth 2023-2028 (%); Data Table on Asia - Year-over-year growth 2023-2028 (%); 9.6 Rest of World (ROW) - Market size and forecast 2023-2028; Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 9.7 US - Market size and forecast 2023-2028; Chart on US - Market size and forecast 2023-2028 ($ million); Data Table on US - Market size and forecast 2023-2028 ($ million); Chart on US - Year-over-year growth 2023-2028 (%); Data Table on US - Year-over-year growth 2023-2028 (%); 9.8 China - Market size and forecast 2023-2028; Chart on China - Market size and forecast 2023-2028 ($ million); Data Table on China - Market size and forecast 2023-2028 ($ million); Chart on China - Year-over-year growth 2023-2028 (%); Data Table on China - Year-over-year growth 2023-2028 (%); 9.9 Germany - Market size and forecast 2023-2028; Chart on Germany - Market size and forecast 2023-2028 ($ million); Data Table on Germany - Market size and forecast 2023-2028 ($ million); Chart on Germany - Year-over-year growth 2023-2028 (%); Data Table on Germany - Year-over-year growth 2023-2028 (%); 9.10 Canada - Market size and forecast 2023-2028; Chart on Canada - Market size and forecast 2023-2028 ($ million); Data Table on Canada - Market size and forecast 2023-2028 ($ million); Chart on Canada - Year-over-year growth 2023-2028 (%); Data Table on Canada - Year-over-year growth 2023-2028 (%); 9.11 India - Market size and forecast 2023-2028; Chart on India - Market size and forecast 2023-2028 ($ million); Data Table on India - Market size and forecast 2023-2028 ($ million); Chart on India - Year-over-year growth 2023-2028 (%); Data Table on India - Year-over-year growth 2023-2028 (%); 9.12 Market opportunity By Geographical Landscape; Market opportunity By Geographical Landscape ($ million); Data Tables on Market opportunity By Geographical Landscape ($ million)
10 Drivers, Challenges, and Opportunity/Restraints: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Impact of drivers and challenges in 2023 and 2028; 10.4 Market opportunities/restraints
11 Competitive Landscape: 11.1 Overview; 11.2 Competitive Landscape; Overview on criticality of inputs and factors of differentiation; 11.3 Landscape disruption; Overview on factors of disruption; 11.4 Industry risks; Impact of key risks on business
12 Competitive Analysis: 12.1 Companies profiled; Companies covered; 12.2 Market positioning of companies; Matrix on companies position and classification; 12.3 Adverum Biotechnologies Inc; Adverum Biotechnologies Inc - Overview; Adverum Biotechnologies Inc - Product / Service; Adverum Biotechnologies Inc - Key offerings; 12.4 Arrowhead Pharmaceuticals Inc.; Arrowhead Pharmaceuticals Inc. - Overview; Arrowhead Pharmaceuticals Inc. - Product / Service; Arrowhead Pharmaceuticals Inc. - Key offerings; 12.5 Attune Pharmaceuticals Inc.; Attune Pharmaceuticals Inc. - Overview; Attune Pharmaceuticals Inc. - Product / Service; Attune Pharmaceuticals Inc. - Key offerings; 12.6 BioCryst Pharmaceuticals Inc.; BioCryst Pharmaceuticals Inc. - Overview; BioCryst Pharmaceuticals Inc. - Product / Service; BioCryst Pharmaceuticals Inc. - Key offerings; 12.7 BioMarin Pharmaceutical Inc.; BioMarin Pharmaceutical Inc. - Overview; BioMarin Pharmaceutical Inc. - Product / Service; BioMarin Pharmaceutical Inc. - Key offerings; 12.8 CENTOGENE NV; CENTOGENE NV - Overview; CENTOGENE NV - Product / Service; CENTOGENE NV - Key offerings; 12.9 Cipla Inc.; Cipla Inc. - Overview; Cipla Inc. - Business segments; Cipla Inc. - Key news; Cipla Inc. - Key offerings; Cipla Inc. - Segment focus; 12.10 CSL Ltd.; CSL Ltd. - Overview; CSL Ltd. - Business segments; CSL Ltd. - Key news; CSL Ltd. - Key offerings; CSL Ltd. - Segment focus; 12.11 Diapharma Group Inc.; Diapharma Group Inc. - Overview; Diapharma Group Inc. - Product / Service; Diapharma Group Inc. - Key offerings; 12.12 Intellia Therapeutics Inc.; Intellia Therapeutics Inc. - Overview; Intellia Therapeutics Inc. - Product / Service; Intellia Therapeutics Inc. - Key offerings; 12.13 Ionis Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc. - Overview; Ionis Pharmaceuticals Inc. - Product / Service; Ionis Pharmaceuticals Inc. - Key news; Ionis Pharmaceuticals Inc. - Key offerings; 12.14 Pharming Group NV; Pharming Group NV - Overview; Pharming Group NV - Business segments; Pharming Group NV - Key offerings; Pharming Group NV - Segment focus; 12.15 Sanofi SA; Sanofi SA - Overview; Sanofi SA - Business segments; Sanofi SA - Key news; Sanofi SA - Key offerings; Sanofi SA - Segment focus; 12.16 Takeda Pharmaceutical Co. Ltd.; Takeda Pharmaceutical Co. Ltd. - Overview; Takeda Pharmaceutical Co. Ltd. - Product / Service; Takeda Pharmaceutical Co. Ltd. - Key news; Takeda Pharmaceutical Co. Ltd. - Key offerings
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Inclusions checklist; Exclusions checklist; 13.3 Currency conversion rates for US$; Currency conversion rates for US$; 13.4 Research methodology; Research methodology; 13.5 Data procurement; Information sources; 13.6 Data validation; Data validation; 13.7 Validation techniques employed for market sizing; Validation techniques employed for market sizing; 13.8 Data synthesis; Data synthesis; 13.9 360 degree market analysis; 360 degree market analysis; 13.10 List of abbreviations; List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market By Geographical Landscape; Exhibits5: Executive Summary - Chart on Market Segmentation by End-user; Exhibits6: Executive Summary - Chart on Market Segmentation by Product; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Company Market Positioning; Exhibits10: Parent Market; Exhibits11: Data Table on - Parent Market; Exhibits12: Market characteristics analysis; Exhibits13: Value Chain Analysis; Exhibits14: Offerings of companies included in the market definition; Exhibits15: Market segments; Exhibits16: Chart on Global - Market size and forecast 2023-2028 ($ million); Exhibits17: Data Table on Global - Market size and forecast 2023-2028 ($ million); Exhibits18: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits19: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits20: Historic Market Size - Data Table on Global Hereditary Angioedema (HAE) Therapeutics Market 2018 - 2022 ($ million); Exhibits21: Historic Market Size - End-user Segment 2018 - 2022 ($ million); Exhibits22: Historic Market Size - Product Segment 2018 - 2022 ($ million); Exhibits23: Historic Market Size - Geography Segment 2018 - 2022 ($ million); Exhibits24: Historic Market Size - Country Segment 2018 - 2022 ($ million); Exhibits25: Five forces analysis - Comparison between 2023 and 2028; Exhibits26: Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits27: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits28: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits29: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits30: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits31: Chart on Market condition - Five forces 2023 and 2028; Exhibits32: Chart on End-user - Market share 2023-2028 (%); Exhibits33: Data Table on End-user - Market share 2023-2028 (%); Exhibits34: Chart on Comparison by End-user; Exhibits35: Data Table on Comparison by End-user; Exhibits36: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits37: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits38: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Exhibits39: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Exhibits40: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits41: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ million); Exhibits42: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%); Exhibits43: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%); Exhibits44: Chart on E-commerce - Market size and forecast 2023-2028 ($ million); Exhibits45: Data Table on E-commerce - Market size and forecast 2023-2028 ($ million); Exhibits46: Chart on E-commerce - Year-over-year growth 2023-2028 (%); Exhibits47: Data Table on E-commerce - Year-over-year growth 2023-2028 (%); Exhibits48: Market opportunity by End-user ($ million); Exhibits49: Data Table on Market opportunity by End-user ($ million); Exhibits50: Chart on Product - Market share 2023-2028 (%); Exhibits51: Data Table on Product - Market share 2023-2028 (%); Exhibits52: Chart on Comparison by Product; Exhibits53: Data Table on Comparison by Product; Exhibits54: Chart on C1-esterase inhibitor - Market size and forecast 2023-2028 ($ million); Exhibits55: Data Table on C1-esterase inhibitor - Market size and forecast 2023-2028 ($ million); Exhibits56: Chart on C1-esterase inhibitor - Year-over-year growth 2023-2028 (%); Exhibits57: Data Table on C1-esterase inhibitor - Year-over-year growth 2023-2028 (%); Exhibits58: Chart on Bradykinin B2 receptor antagonist - Market size and forecast 2023-2028 ($ million); Exhibits59: Data Table on Bradykinin B2 receptor antagonist - Market size and forecast 2023-2028 ($ million); Exhibits60: Chart on Bradykinin B2 receptor antagonist - Year-over-year growth 2023-2028 (%); Exhibits61: Data Table on Bradykinin B2 receptor antagonist - Year-over-year growth 2023-2028 (%); Exhibits62: Chart on Kallikrein inhibitor - Market size and forecast 2023-2028 ($ million); Exhibits63: Data Table on Kallikrein inhibitor - Market size and forecast 2023-2028 ($ million); Exhibits64: Chart on Kallikrein inhibitor - Year-over-year growth 2023-2028 (%); Exhibits65: Data Table on Kallikrein inhibitor - Year-over-year growth 2023-2028 (%); Exhibits66: Chart on Others - Market size and forecast 2023-2028 ($ million); Exhibits67: Data Table on Others - Market size and forecast 2023-2028 ($ million); Exhibits68: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibits69: Data Table on Others - Year-over-year growth 2023-2028 (%); Exhibits70: Market opportunity by Product ($ million); Exhibits71: Data Table on Market opportunity by Product ($ million); Exhibits72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits73: Chart on Market share By Geographical Landscape 2023-2028 (%); Exhibits74: Data Table on Market share By Geographical Landscape 2023-2028 (%); Exhibits75: Chart on Geographic comparison; Exhibits76: Data Table on Geographic comparison; Exhibits77: Chart on North America - Market size and forecast 2023-2028 ($ million); Exhibits78: Data Table on North America - Market size and forecast 2023-2028 ($ million); Exhibits79: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits80: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits81: Chart on Europe - Market size and forecast 2023-2028 ($ million); Exhibits82: Data Table on Europe - Market size and forecast 2023-2028 ($ million); Exhibits83: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits84: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits85: Chart on Asia - Market size and forecast 2023-2028 ($ million); Exhibits86: Data Table on Asia - Market size and forecast 2023-2028 ($ million); Exhibits87: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits88: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits89: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits90: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million); Exhibits91: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits92: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits93: Chart on US - Market size and forecast 2023-2028 ($ million); Exhibits94: Data Table on US - Market size and forecast 2023-2028 ($ million); Exhibits95: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits96: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits97: Chart on China - Market size and forecast 2023-2028 ($ million); Exhibits98: Data Table on China - Market size and forecast 2023-2028 ($ million); Exhibits99: Chart on China - Year-over-year growth 2023-2028 (%); Exhibits100: Data Table on China - Year-over-year growth 2023-2028 (%); Exhibits101: Chart on Germany - Market size and forecast 2023-2028 ($ million); Exhibits102: Data Table on Germany - Market size and forecast 2023-2028 ($ million); Exhibits103: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits104: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits105: Chart on Canada - Market size and forecast 2023-2028 ($ million); Exhibits106: Data Table on Canada - Market size and forecast 2023-2028 ($ million); Exhibits107: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibits108: Data Table on Canada - Year-over-year growth 2023-2028 (%); Exhibits109: Chart on India - Market size and forecast 2023-2028 ($ million); Exhibits110: Data Table on India - Market size and forecast 2023-2028 ($ million); Exhibits111: Chart on India - Year-over-year growth 2023-2028 (%); Exhibits112: Data Table on India - Year-over-year growth 2023-2028 (%); Exhibits113: Market opportunity By Geographical Landscape ($ million); Exhibits114: Data Tables on Market opportunity By Geographical Landscape ($ million); Exhibits115: Impact of drivers and challenges in 2023 and 2028; Exhibits116: Overview on criticality of inputs and factors of differentiation; Exhibits117: Overview on factors of disruption; Exhibits118: Impact of key risks on business; Exhibits119: Companies covered; Exhibits120: Matrix on companies position and classification; Exhibits121: Adverum Biotechnologies Inc - Overview; Exhibits122: Adverum Biotechnologies Inc - Product / Service; Exhibits123: Adverum Biotechnologies Inc - Key offerings; Exhibits124: Arrowhead Pharmaceuticals Inc. - Overview; Exhibits125: Arrowhead Pharmaceuticals Inc. - Product / Service; Exhibits126: Arrowhead Pharmaceuticals Inc. - Key offerings; Exhibits127: Attune Pharmaceuticals Inc. - Overview; Exhibits128: Attune Pharmaceuticals Inc. - Product / Service; Exhibits129: Attune Pharmaceuticals Inc. - Key offerings; Exhibits130: BioCryst Pharmaceuticals Inc. - Overview; Exhibits131: BioCryst Pharmaceuticals Inc. - Product / Service; Exhibits132: BioCryst Pharmaceuticals Inc. - Key offerings; Exhibits133: BioMarin Pharmaceutical Inc. - Overview; Exhibits134: BioMarin Pharmaceutical Inc. - Product / Service; Exhibits135: BioMarin Pharmaceutical Inc. - Key offerings; Exhibits136: CENTOGENE NV - Overview; Exhibits137: CENTOGENE NV - Product / Service; Exhibits138: CENTOGENE NV - Key offerings; Exhibits139: Cipla Inc. - Overview; Exhibits140: Cipla Inc. - Business segments; Exhibits141: Cipla Inc. - Key news; Exhibits142: Cipla Inc. - Key offerings; Exhibits143: Cipla Inc. - Segment focus; Exhibits144: CSL Ltd. - Overview; Exhibits145: CSL Ltd. - Business segments; Exhibits146: CSL Ltd. - Key news; Exhibits147: CSL Ltd. - Key offerings; Exhibits148: CSL Ltd. - Segment focus; Exhibits149: Diapharma Group Inc. - Overview; Exhibits150: Diapharma Group Inc. - Product / Service; Exhibits151: Diapharma Group Inc. - Key offerings; Exhibits152: Intellia Therapeutics Inc. - Overview; Exhibits153: Intellia Therapeutics Inc. - Product / Service; Exhibits154: Intellia Therapeutics Inc. - Key offerings; Exhibits155: Ionis Pharmaceuticals Inc. - Overview; Exhibits156: Ionis Pharmaceuticals Inc. - Product / Service; Exhibits157: Ionis Pharmaceuticals Inc. - Key news; Exhibits158: Ionis Pharmaceuticals Inc. - Key offerings; Exhibits159: Pharming Group NV - Overview; Exhibits160: Pharming Group NV - Business segments; Exhibits161: Pharming Group NV - Key offerings; Exhibits162: Pharming Group NV - Segment focus; Exhibits163: Sanofi SA - Overview; Exhibits164: Sanofi SA - Business segments; Exhibits165: Sanofi SA - Key news; Exhibits166: Sanofi SA - Key offerings; Exhibits167: Sanofi SA - Segment focus; Exhibits168: Takeda Pharmaceutical Co. Ltd. - Overview; Exhibits169: Takeda Pharmaceutical Co. Ltd. - Product / Service; Exhibits170: Takeda Pharmaceutical Co. Ltd. - Key news; Exhibits171: Takeda Pharmaceutical Co. Ltd. - Key offerings; Exhibits172: Inclusions checklist; Exhibits173: Exclusions checklist; Exhibits174: Currency conversion rates for US$; Exhibits175: Research methodology; Exhibits176: Information sources; Exhibits177: Data validation; Exhibits178: Validation techniques employed for market sizing; Exhibits179: Data synthesis; Exhibits180: 360 degree market analysis; Exhibits181: List of abbreviations